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Abstract Population biobanks offer new opportunities for
public health, are rudimentary for the development of its
new branch called Public Health Genomics, and are impor-
tant for translational research. This article presents organi-
zational models of population biobanks in selected
European countries. Review of bibliography and websites
of European population biobanks (UK, Spain, Estonia).
Some countries establish national genomic biobanks (DNA
banks) in order to conduct research on new methods of
prevention, diagnosis and treatment of the genetic and life-
style diseases and on pharmacogenetic research. Individual
countries have developed different organizational models of
these institutions and specific legal regulations regarding
various ways of obtaining genetic data from the inhabitants,
donors’ rights, organizational and legal aspects. Population
biobanks in European countries were funded in different
manners. In light of these solutions, the authors discuss
prospects of establishing a Polish national genomic biobank
for research purpose. They propose the creation of such an
institution based on the existing network of blood-donation
centres and clinical biobanks in Poland.
Keywords DNAbanking.Geneticepidemiology.
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Introduction
Biobanks, gradually begin to play an increasingly important
role in studying the determinants of populations’ health and
in shaping proper prevention programs and health policies.
The Expert Group of the European Commission defines
biobanks as various types of “biological samples them-
selves, plus the related databases” (http://ec.europa.eu).
The Oganisation for Economic Co-operation and Devel-
opment (OECD) documents, on the other hand, characterize
biobanks as „structured resources that can be used for the
purpose of genetic research and which include: human bio-
logical materials and/or information generated from the
analysis of the same; and extensive associated information”
(http://www.oecd.org). They also emphasize that biobanks
can be used in research on human genetics and the relation-
ships between genetic, environmental and life-style factors
in shaping population health (http://www.oecd.org). Bio-
banks are diverse in terms of the purpose for which they
collect the biological material. They exist for clinical pur-
poses (transplants, blood transfusions, genetic diagnosis),
research (e.g. research on neurodegenerative diseases,
monozygotic siblings, isolated populations, pharmacoge-
netic studies), police and courts, and others (e.g. Education-
al purpose). Some of the projects related to biobanking are
carried out on a large-scale, as exemplified by the genomic
biobanks of entire populations, also called population
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DOI 10.1007/s13353-012-0082-4biobanks (Swede et al. 2007). Public trust is the most
important predictor of the publics’ intention to participate
in biobank research (Crithchley et al. 2010; Kettis-Lindblad
et al. 2005).
The most important hopes connected with the develop-
ment of biobanks are: a better recognition of genetic and
environmental factors of the hereditary diseases, examining
people’s susceptibility to specific diseases (Frazier et al.
2008; Wang et al. 2010; Brozek et al. 2011; Myszka et al.
2011); more effective personalized preventive care (e.g. the
modern spectrometry allows detection of more than 30
metabolic disorders using the neonatal screening blood spot)
(Sharrard and Pollitt 2007), adaptation of the treatment to
the patient’s individual genetic characteristics by develop-
ment of pharmacogenetics (personalized medicine) (Roses
2000; Matimba et al. 2008; Szczepanek et al. 2011) invent-
ing innovative drug therapies and discovering new bio-
markers of many diseases with the use of modern
sequencing technologies (Pareek et al. 2011). DNA obtained
from archived tissues, blood films and slides may be useful
to establish the molecular diagnosis of a deceased patient
and this information may be of value for relatives even after
10–20 years (Godard et al. 2003). Population biobanks may
also allow to trace the evolution of genetic changes in
subsequent generations, allowing an improved understand-
ing of pathogenic mechanisms leading to the development
of many diseases caused by hereditary factors or the inter-
action of genetic and environmental factors (Founti et al.
2009; Inczédy-Farkas et al. 2010). The development of
population biobanks will also isolate the group of patients
unsusceptible to certain diseases, who will not require the
unnecessary and expensive diagnostic, which in turn will
allow for a rational management of financial resources in the
health care system (Roden et al. 2008). These opportunities
contributed to the development of a new field within public
health called Community Genetics or Public Health Genet-
ics/Genomics (PHG). PHG is defined as the responsible and
effective translation of genome-based knowledge and tech-
nologies for the benefit of population health (definition of
Bellagio Group on Public Health Genomics)( http://www.
phgen.nrw.de). PHD assesses the impact of genes and their
interaction with behavior, diet (nutrigenomics) and the en-
vironment on the population’s health (e.g. ALSPAC the
Avon Longitudinal Study of Pregnancy and Childhood -a
gene-environmental research focused on children’s health)
(www.alspac.bristol.ac.uk).
There are many international initiatives in PHG that
promote the translation of genome-based science and tech-
nology into improvements in population health, e.g. HuGE-
Net (Human Genome Epidemiology Network)( www.cdc.
gov/genomics/), P3G Consortium (Public Population Project
in Genomics) (www.p3g.org/), GraPH-Int(The Genome-based
Research and Population Health International Network)
(www.graphint.org/)a n dG R C( Genomic Resource Centre)
developed by WHO (www.graphint.org/). Noteworthy is the
project of the Biobanking and Biomolecular Resources Re-
search Infrastructure (BBMRI) (www.who.int/genomics/en/).
Its main purpose is to connect, within the next few years, the
existing genomic biobanks from different countries of the
European Union in one research network. This may become
the basis for an integrated research, leading to a better under-
standing of factors affecting the health disparities in European
countries, and to a more reasonable measure of improving the
health of the European population.
The objective of this article is to present organizational
solutions to population biobanks in selected European
countries. It appears that population biobanks are in fact
diverse in this respect, and not only researchers and devel-
opment centres possessing public finances are involved in
the process of their creation, but in recent years, under the
auspices of associations, foundations and private companies
multiply the projects of gathering genetic materials. Cur-
rently, population biobanks are experiencing a rapid devel-
opment in European countries, which accelerated sharply
after sequencing of the human genome in 2000. Gradually,
they become a part of the health care system not only by
creating new opportunities for research, but also by giving
the opportunity to implement effective measures to preserve
the health of the European population (Swede et al. 2007;
McCarthy et al. 2008; Litton 2011). In light of organization-
al solutions of European contries, the authors discuss pros-
pects of establishing a Polish national genomic biobank for
research purpose.
Methods
Review of bibliography and websites of European popula-
tion biobanks. We reviewed in PubMed database articles
which concern population biobanks focusing on organiza-
tional models of these institutions and specific legal regu-
lations regarding various ways of obtaining genetic data
from the inhabitants, donors’ rights, organizational and legal
aspects. We analysed more deeply UK Biobank, Spanish
national biobank and Estonian biobank because of their
interesting and different organizational aspects that can be
used in establishement of new population biobanks. Model
of a proposed Polish national genomic biobank for research
purposes was discussed regarding Polish organizational and
legal conditions.
Results
Contemporary, an increasing number of projects on popula-
tion biobanks, aimed at collecting biological samples and
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Some countries establish national genomic biobanks (DNA
banks) in the hope of an advanced understanding and im-
proved prevention of genetic diseases (Hirtzlin et al. 2003).
It is calculated that at the end of 2007 there were about 120
population biobanks worldwide, mainly in Europe and
North America but also in Asia (e.g. China). In Europe,
most active countries in the creation of population biobanks
are the countries of Western Europe and Scandinavia. The
countries of Central and Eastern Europe, however, have
already implemented such a project in Estonia, and Hungary
and Poland are in the process of its preparation (Pawlikowski
and Sak 2010). Below: there are three different organizational
models of genomic biobanking: the British, Spanish and
Estonian.
UK Biobank
The UK Biobank was created in order to conduct research
on new methods of prevention, diagnosis and treatment of
the genetic and lifestyle diseases. The Wellcome Trust
Foundation, as well as public entities (Medical Research
Council, the Scottish Government, the British Heart Foun-
dation, and the Northwest Regional Development Agency)
played an important role in its creation. The Scientific
Committee and the international bioethical committee
supervized these activities. What is more, there were six
regional centres working together and 22 British universities
involved. First preparations for establishing of the UK Bio-
bank occurred in the late 1990s of the twentieth century. In
2000–2001 public consultations concerning the public per-
ception of biobanking were conducted. In 2006, a pilot
study on a group of 4000 residents of Manchester was
carried out and relevant legal regulations established
(www.ukbiobank.ac.uk). In the next phase of creating the
biobank, after planning of the recruitment process based on
drawn conclusions from the pilot study, the UK Biobank
obtained samples from more than 500 thousand people aged
40-69. Participants were voluntarily recruited based on the
data contained in the databases of the National Health Ser-
vice. Founders of the biobank distributed to hundreds of
thousands of potential donors an invitation to participate in
the project. Recipients, who agreed to participate in the
study, gave blood, urine and saliva samples; passed the basic
diagnostic tests and filled out a questionnaire. Acquired
genomic samples are kept for a period of 20-30 years, and
made available as anonymous only to researchers’ whose
projects receive the approval of the ethics committee. Sci-
entists from abroad may also apply for the access to the
biobank’s resources. Gaining profits from the research may
be allowed, e.g. by pharmaceutical companies which will
conduct studies with the usage of these resources (Yuille et
al. 2010). The test results are not made available to donors;
however, they have a possibility of withdrawing data from
the database. Biobank is insured against any damage related
to the donation or storage of samples from the participants
of the study (http://www.ukbiobank.ac.uk/). An important
feature of the UK Biobank is its openness to the multicul-
tural and multilingual potential donors living in the United
Kingdom. Information materials intended for potential
donors are translated into many vernacular languages.
Spanish National Biobank (Banco Nacional de ADN)
Spanish National Biobank (Banco Nacional de ADN)
was established in 2004 by the Genome Spain Founda-
tion (Fundacion Genome Espana), in collaboration with
the University of Salamanca. The purpose of its creation
was to support research on genetic diversity of the population
living in Spain, the development of emerging diseases in the
process of human evolution and development of new treat-
ments of lifestyle diseases, including pharmacogenetic re-
search. The specific objectives of El Banco Nacional de
ADN include the study of determinants of susceptibility to
certain diseases, early diagnosis,improvement ofdisease clas-
sification, the search for new prognostic factors, and optimi-
zation of individual treatment, monitoring of effects of
treatment, and transferring the results of basic examinations
to clinical reality.
Biobank centre is located in Salamanca, at the local
university, and the sanitary inspectorate of the Castile and
Leon province, the founding the Spanish Genome Founda-
tion, an external scientific committee and a bioethical com-
mittee, exercises supervision. The last two supervisors have
international members. The advisory group includes repre-
sentatives of all regional blood donation centres and blood
banks. Apart from the biobanks’ headquarters, since 2006
the biobank consists of four research institutes from other
provinces of Spain, which specialize in research on certain
diseases. Collecting samples is based on cooperation with
the regional blood donation centres and blood banks. These
institutions take samples of blood and are responsible for
collecting data and completing the appropriate survey ques-
tionnaire containing questions directed to the donor about
his lifestyle, diet, family medical history, etc. DNA samples
are sent to the headquarters in Salamanca, where they are
encoded, prepared and stored. Access to the specimens is
available for researchers from Spain and those from abroad
who collaborate with the Spanish scientists. The ethics
committee must approve research projects.
In 2006, an additional network of specialized centres and
research networks on specific diseases: cardiovascular dis-
eases (Barcelona), metabolic (Barcelona), neuropsychiatric
(Reus) and oncology (Salamanca), was created. Specialized
centres collect, store and conduct tests on samples of bio-
logical material from persons suffering from specific types
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collects samples from individuals after myocardial infarc-
tion, coronary artery disease, hypertension, arrhythmia, etc.
These centres collaborate with other national centres con-
ducting research in the same fields. The donors have the
opportunity to withdraw their consent and samples collected
by the biobank, however they do not have access to indi-
vidual test results, because samples sent to the researchers
are anonymized, namely where the personal data and the
genetic data of the donor are irreversibly separated (http://
www.bancoadn.org/en/home.htm). Available for researchers
is therefore the sample with genomic data obtained
concerning the state of health of the donor but without any
possibility of restoring his identity.
Estonian population biobank (Estonian Gene Bank)
Estonian Genome Project was the basis for the creation of
the population GenBank, whose goal is to gather samples
from approximately 1 million inhabitants of Estonia and
Latvia. The legal basis for its establishment was a relevant
legal act (Human Genome Research Act), which came into
force in 2001. It regulated the research on human genetics
and the protection of the donors (confidentiality, non-
discrimination by insurers and employers), and called into
existence a national genomic biobank. Participation in the
project was voluntary and the participants had access to their
results (the right to know), but also had a guaranteed right
not to know. They could withdraw the previously granted
consent and demand the destruction of data allowing for
their identification. Biobank is supervized by: a bioethical
committee (28 members), a supervisory committee (consist-
ing of nine members of parliament, government and the
Estonian Academy of Sciences). Funding is based on the
principles of public-private partnership. By agreement with
the government, the project is pursued by a private non-
profit foundation (Estonian Genome Project Foundation),
which became the legal owner of the collected material and
data. The right to access the data is given to the family
doctors (who take care of the donors) and researchers work-
ing in the Estonian research institutes; however, the Ethics
Committee must approve their project. Intellectual property
rights are shared between researchers and the foundation.
In the first phase of the project (until 2003), about 100
family doctors were involved and samples were taken from
about 10,000 people. In the second (main) phase, between
the years 2003–2007, it was intended to gather samples
from approximately three-quarters of the country’s popula-
tion (the population of Estonia, according to data from 2010
was 1,340,000 people (http://www.stat.ee/main-indicators)
engaging in it about 800 persons who collected these sam-
ples. This plan was not fully executed. In 2009, the biobank
gathered samples and data from 40,000 donors, and at the
end of 2010 had only 50,000 samples. Each research
participant gave about 50 ml of blood and filled out a
questionnaire which included questions on personal data,
environmental conditions, diet, workplace, lifestyle, clinical
data (e.g. prior and current diseases), and family medical
history to a third generation back. After collecting of the
biological material, personal data assigned to samples were
coded. Informed consent form was kept in the coding centre,
which is also responsible for the anonymization of data or if
necessary for the identification of donors (e.g. in the case of
a request to withdraw data from the biobank) (http://www.
geenivaramu.ee/index.php?id0462).
Discussion and prospects of creating a population genomic
biobank in Poland
Population biobanks were organized in a different manners.
For this purpose new, distinct from the existing institutions
that collects samples of biological material from volunteers,
or used existing samples and data after obtaining a new
consent from the donors were created. Additional possibility
was the creation of systems of cooperation between existing
biobanking institutions (e.g. blood-donation centres.). Indi-
vidual countries have developed different organizational
models of these institutions and specific methods of legal
regulations (Deschenes and Sallke 2005).
The British and Estonian model seem quite expensive,
what is more, the British model is based on specific, state
system of National Health Service. The Spanish model, in
turn, is characterized by economy and simplicity of the
organizational structure (using the existing organizational
structure of regional blood donation centres) and at the same
time is tailored to the population inhabiting a large area of
varying population density. A valuable component of the
collaboration with general practitioners included in the Es-
tonian solution, or the clear focus on selected donors in the
British biobank (including those in a specific age group)
should be noted. A good concept is to work with leading
scientific institutions conducting research on specific hered-
itary diseases (as in the case of the Spanish biobank) and
medical universities (e.g. UK Biobank), which will allow
for a rational and effective management of accumulated
scientific resources. It is extremely important to create an
appropriate infrastructure and data protection system, which
will allow for cooperation with other national and foreign
scientific centres and within the BBMRI network (Kauffman
and Cambon-Thomsen 2008;D h i re ta l .2008;G o s t e ve ta l .
2011;A s s l a b e ra n dZ a t l o u k a l2007).
Implementation of any new population biobank project
should be preceded by a serious social debate, public opin-
ion surveys and the introduction of the necessary legal
changes governing the biobank in accordance with the rec-
ommendations of international organizations (Crithchley et
162 J Appl Genetics (2012) 53:159–165al. 2010; Winickoff and Neumann 2005; http://www.oecd.
org). The process of establishing a new genomic biobanks
(e.g. the Polish genomic biobank), should rely on the select-
ed items from other models and take into account local
organizational, legal and social conditions.
Currently in Poland, there is no nationwide organization
obtaining genetic material for populationstudies (Pawlikowski
et al. 2010). There are only local (university or working at the
regional oncology centres) facilities, which obtain genetic
material for scientific research in a very limited extent. Con-
temporarily in Poland, discussion began on the subject of
organizational, legal and ethical basis of the creation of a
national genomic biobank.
Results of the expertise, completed in November 2009
suggest the possibility of creating such a biobank in Polish
conditions (Pawlikowski and Sak 2010). Organizational
structure of the Polish genomic biobank should consist of
two levels, i.e. composed of a superior national coordinating
centre and subordinate regional, biobanking and specialized
centres (targeted on research on specific disease entities).
Regional biobanking centres together with specialized bio-
banks should obtain samples and data from donors and
transfer them to the national coordinating centre where
samples and data should be encoded, processed and stored
(Fig. 1).
The establishment, from the first, of a population biobank
in Polish conditions would be a very expensive and time-
consuming task. It would be more beneficial to base it on the
already existing Polish biobanking institutions, e.g. primar-
ily on the blood donation centres and research centres. They
have qualified staff and infrastructure, which after necessary
modifications (and possibly a small expansion) could lead to
their integration into the structure of a national genomic
biobank. In organizational terms, it would be best to include
the already existing biobanking institutions as “sectors” of
the system of the Polish genomic biobank. They could retain
the availability of the realization of the existing tasks, and
simultaneously make available facilities and personnel for
the needs of population biobanking.
Established a few years ego, National Centre for Tissue
and Cell Banking (Krajowe Centrum Bankowania Tkanek i
Komórek - KCBTiK) could serve as a national coordinating
centre. Until now, the tasks undertaken by KCBTiK was the
coordination of the activities of other national and regional
tissue and cell banks (biobanks created mainly for clinical
and transplantation purposes), and acting as a place of
reference, consultation and supervision in strictly medical
terms. Sectoral use of KCBTiK as a national coordinating
centre of the Polish population biobank would be beneficial
due to the possibility of inclusion into the newly formed
Basic biobanks
Regional blood 
donation centre
Specialised 
Biobanks
The national coordinating 
centre 
National Centre for Tissue and 
Cell Banking (KCBTiK)
Bioethical committee Scientific advisory board
BBMRI
Fig. 1 Two-level structure of
the project of the Polish
National Genomic Biobank and
the system of supervision
J Appl Genetics (2012) 53:159–165 163biobank, the existing tissue and cells biobanks, which
currently report their activities to the KCBTiK (Fig. 1).
The regional biobanking centres could be based on the
regional blood donation and haemotherapy centres in
Poland. The already existing research centres (medical uni-
versities, oncology centres, Polish Academy of Sciences,
genetic diagnostic centres) may fulfil the function of spe-
cialist biobanks directed at the diagnosis of certain types of
diseases:.
It is worthly to postulate for the establishment of an
external scientific committee and ethics committee for the
supervision on the correctness of the collection, storage and
transfer of the genetic material and data for scientific re-
search. In terms of Polish legal solutions currently in force,
there should be an amendment of the “Transplant act”
(Ustawa z dnia 1 lipca 2005r)o ran e wl a ws h o u l db e
written which would autonomously and comprehensively
regulate the issue of biobanking. In the case of a successful
process of creating a national biobank in Poland for the
purpose of genomic research there is the possibility of
incorporating it into other European biobanks and other
entities conducting research within the confines of currently
forming Biobanking and Biomolecular Resources Research
Infrastructure (BBMRI) (http://www.bbmri.eu/).
Key points
& Population biobanks are important for the development of
the public health genomics and personalized medicine.
& Some European countries have developed different or-
ganizational models of population biobanks and specific
legal regulations.
& Population biobanks can be created in collaboration with
universities, general practitioners, blood donation centres
and scientific research institutes.
& Population biobanks can be founded basing on the
public-privacy partnership.
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